Scinai Immunotherapeutics (SCNI) Accumulated Expenses (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 12 years of Accumulated Expenses data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (changed N/A YoY), and the FY2025 full-year result was $849000.0, up 61.1% from the prior year.
• Accumulated Expenses advanced to $1.6 million in Q1 2026, from $849000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q1 2026 to a low of $388000.0 in Q4 2023.
• A 5-year average of $747600.0 and a median of $618000.0 in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 99.97% in 2022 and surged 61.1% in 2025, its largest moves.
• Tracing SCNI's Accumulated Expenses over 5 years: stood at $484000.0 in 2022, then fell by 19.83% to $388000.0 in 2023, then jumped by 35.82% to $527000.0 in 2024, then soared by 61.1% to $849000.0 in 2025, then surged by 82.8% to $1.6 million in 2026.
• Business Quant data shows SCNI's Accumulated Expenses at $1.6 million in Q1 2026, $849000.0 in Q4 2025, and $964000.0 in Q2 2025.